Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin,resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia |
| |
Authors: | C. Otto B. Otto R. J. A. Frost M. Vogeser A. F. H. Pfeiffer J. Spranger K. G. Parhofer |
| |
Affiliation: | (1) Medical Department 2 — Grosshadern, University Hospital Munich, Marchioninistrasse 15, D-81377 Munich, Germany;(2) Medical Department — Innenstadt, University Hospital Munich, Munich, Germany;(3) Institute of Clinical Chemistry — Grosshadern, University Hospital Munich, Munich, Germany;(4) Department of Clinical Nutrition, German Institute of Human Nutrition, Bergholz-Rehbrücke, Germany;(5) Department of Endocrinology, Diabetes and Nutrition Charité-University Medicine, Campus Benjamin Franklin, Berlin, Germany |
| |
Abstract: | Lipid-lowering therapy is associated with reduced cardiovascular risk. The aim of the present study was to investigate whether lipid-lowering therapy might be associated with changes in the concentrations of metabolically important hormone concentrations. We performed a randomised cross-over open-label trial with atorvastatin (10 mg/day) and fenofibrate (200 mg/day), each for 6 weeks separated by a 6-week washout period in 13 patients (5 men, 8 women, age 60.0±6.8 years, body mass index 30.0±3.0 kg/m2) with type 2 diabetes mellitus and mixed hyperlipoproteinaemia. Plasma ghrelin (RIA, Phoenix Pharmaceuticals, Mountain View, CA, USA), adiponectin (ELISA, Biovendor, Heidelberg, Germany) as well as resistin (ELISA, Linco Research, St. Charles, MO, USA) concentrations were measured before and after atorvastatin as well as before and after fenofibrate. Ghrelin (462±84 pg/ml before vs. 464±102 pg/ml after atorvastatin, n.s.; 454±85 pg/ml before vs. 529±266 pg/ml after fenofibrate, n.s.), resistin (24.4±7.4 pg/ml before vs. 23.7±9.1 pg/ml after atorvastatin, n.s.; 23.4±8.2 pg/ml before vs. 19.9±5.5 pg/ml after fenofibrate, n.s.), adiponectin (10.89±5.33 pg/ml before vs. 12.41±5.75 pg/ml after atorvastatin, n.s.; 12.58±9.87 pg/ml before vs. 10.27±5.23 pg/ml after fenofibrate, n.s.) and insulin levels did not change significantly during lipid-lowering therapy. In patients with type 2 diabetes and mixed hyperlipoproteinaemia, short-term atorvastatin as well as fenofibrate therapy had no significant effects on adiponectin, ghrelin or resistin levels. |
| |
Keywords: | Adipocytokines Insulin resistance Diabetes Statin Fibrate |
本文献已被 PubMed SpringerLink 等数据库收录! |
|